Table 4.
Clinical, demographical and laboratory characteristics of steatotic and non-steatotic subpopulations with AILD.
| Value | Non-steatotic (n = 343) | Steatotic (n = 90) | p value |
|---|---|---|---|
| Female, % (n) | 68.5% (235) | 76.7% (69) | 0.155 |
| Age, years | 49.0 (16–85) | 54.0 (24–80) | <0.001 |
| Cirrhosis, % (n) | 24.2% (83) | 31.1% (28) | 0.223 |
| BMI, kg/m² | 24.9 (12.1-42.5) | 30.0 (18.8-46.5) | <0.0001 |
| Haemoglobin, g/dl | 13.48 (±1.7) | 14.0 (±1.4) | <0.001 |
| Platelets, 109/L | 214.35 (±90.5) | 229.1 (±85.8) | 0.284 |
| Albumin, g/L | 36.0 (±5.5) | 37.4 (±4.4) | 0.205 |
| Bilirubin, mg/dl | 0.8 (0.2-25.6) | 0.6 (0.2-14.3) | <0.001 |
| HbA1c,% | 5.3 (3.8-10.4) | 5.7 (4.2-13.4) | <0.01 |
| Cholesterol, mg/dl | 196.0 (52.0-391.0) | 212.5 (80.0-335.0) | 0.091 |
| Triglycerides, mg/dl | 97 (41-401) | 169 (70-694) | <0.0001 |
| AST, U/L | 56 (11-1,262) | 41 (17-753) | 0.019 |
| ALT, U/L | 79 (14-2,506) | 62 (20-1,434) | <0.01 |
| GGT, U/L | 141 (15.0-1,631) | 105 (15-1,251) | 0.033 |
| AP, U/L | 146 (35-1,011) | 11 (28-1,022) | <0.0001 |
| IgG, g/L | 15.0 (4.2-56.6) | 14.8 (6.5-29.4) | 0.585 |
| Anti-diabetic treatment, % (n) | 7.6% (26) | 16.7% (15) | 0.014 |
| Immune-suppressive medication (any form), % (n) | 39.9% (137) | 46.7% (42) | 0.281 |
| Prednisolone, % (n) | 31.2% (107) | 37.8% (34) | 0.162 |
| UDCA, % (n) | 30.3% (104) | 21.1% (19) | 0.089 |
Nominal variables are presented as frequencies (and total numbers). Differences were calculated using the chi-square test or Fisher´s exact-test as appropriate. Continuous variables are presented as median (range) or mean (± standard deviation), as appropriate. Differences between groups were compared using Mann-Whitney-U-test.
Values in bold denote statistical significance.
AILD, autoimmune/immune mediated liver disease; ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index, GGT, gamma glutamyl transferase; HbA1c, glycated hemoglobin; IgG, immunoglobulin G; UDCA, ursodeoxycholic acid.